TCR-1672

TCR-1672 is an orally administered, second-generation, highly selective small molecule antagonist of the P2X3 receptor (P2X purinoceptor 3), developed primarily for the treatment of refractory chronic cough (RCC). The drug is also under investigation for asthma, endometriosis pain, cancer pain, and neuropathic pain. Overactivation of the P2X3 receptor—a ligand-gated ion channel in the purine receptor family—is associated with hypersensitization of sensory neurons leading to persistent cough and certain types of pain. By blocking calcium ion influx through the P2X3 receptor initiated by adenosine triphosphate (ATP), TCR-1672 inhibits this pathway to reduce symptoms. The drug is being developed by Sino Biopharmaceutical and its subsidiary Beijing Tide Pharmaceutical[1][4][6].